Faron Pharmaceuticals Oy Holding(s) in Company
June 24 2024 - 7:45AM
RNS Regulatory News
RNS Number : 6230T
Faron Pharmaceuticals Oy
24 June 2024
TR-1: Standard form for notification
of major holdings
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and
to the FCA in Microsoft Word format if possible)
i
|
|
|
|
1a.
Identity of the issuer or the underlying issuer of existing shares
to which voting rights are attached ii:
|
Faron
Pharmaceuticals Ltd
|
|
1b.
Please indicate if the issuer is a non-UK issuer
(please mark with an "X" if
appropriate)
|
|
Non-UK issuer
|
X
|
|
2.
Reason for the notification (please
mark the appropriate box or boxes with an "X")
|
|
An acquisition or disposal of voting
rights
|
X
|
|
An acquisition or disposal of
financial instruments
|
X
|
|
An event changing the breakdown of
voting rights
|
|
|
Other (please specify)
iii: Change due the Share Offering
|
X
|
|
3.
Details of person subject to the notification
obligation iv
|
|
Name
|
Timo Syrjälä
|
|
City and country of registered office
(if applicable)
|
Lausanne, Switzerland
|
|
4.
Full name of shareholder(s) (if
different from 3.) v
|
|
Name
|
20.6.2024
|
|
City and country of registered office
(if applicable)
|
20.6.2024
|
|
5.
Date on which the threshold was crossed or reached
vi:
|
20.6.2024
|
|
6.
Date on which issuer notified
(DD/MM/YYYY):
|
20.6.2024
|
|
7.
Total positions of person(s) subject to the notification
obligation
|
|
|
% of
voting rights attached to shares (total of 8. A)
|
%
of voting rights through
financial instruments
(total of 8.B 1 + 8.B 2)
|
Total of
both in % (8.A + 8.B)
|
Total number of voting rights held in
issuer (8.A + 8.B) vii
|
|
Resulting situation on the date on
which threshold was crossed or reached
|
15,32%
|
|
|
16,024,023
|
|
Position of previous notification
(if
applicable)
|
18,48%
|
|
|
13,308,001
|
|
|
|
|
|
|
| |
|
8.
Notified details of the resulting situation on the date on which
the threshold was crossed or reached
viii
|
|
A:
Voting rights attached to shares
|
|
Class/type of
shares
ISIN code (if possible)
|
Number of voting rights ix
|
% of
voting rights
|
|
Direct
(DTR5.1)
|
Indirect
(DTR5.2.1)
|
Direct
(DTR5.1)
|
Indirect
(DTR5.2.1)
|
|
FI4000153309
|
5,526,277
|
10,497,796
|
5,28%
|
10,03%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8. A
|
16,024,023
|
15,32%
|
|
|
|
B 1:
Financial Instruments according to DTR5.3.1R (1)
(a)
|
|
Type
of financial instrument
|
Expiration
date x
|
Exercise/
Conversion Period xi
|
Number of voting rights that may be acquired if the instrument
is
exercised/converted.
|
% of
voting rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8. B 1
|
|
|
|
|
|
B 2:
Financial Instruments with similar economic effect according to
DTR5.3.1R (1) (b)
|
|
Type
of financial instrument
|
Expiration
date x
|
Exercise/
Conversion Period xi
|
Physical or cash
Settlement xii
|
Number of voting rights
|
% of
voting rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8.B.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
9.
Information in relation to the person subject to the notification
obligation (please mark
the
applicable box with an
"X")
|
|
Person subject to the notification
obligation is not controlled by any natural person or legal entity
and does not control any other undertaking(s) holding directly or
indirectly an interest in the (underlying) issuer
xiii
|
|
|
Full chain of
controlled undertakings through which the voting rights and/or
the
financial instruments are effectively held starting with the
ultimate controlling natural person or legal entity (please add additional rows as necessary)
xiv
|
X
|
|
Name
xv
|
% of voting rights if it
equals or is higher than the notifiable threshold
|
% of voting rights through
financial instruments if it equals or is higher than the notifiable
threshold
|
Total of both if it equals or
is higher than the notifiable threshold
|
|
Timo Syrjälä (Direct)
|
5,28%
|
|
5,28%
|
|
Acme Investments SPF Sarl
(Indirect)
|
10,03%
|
|
10,03%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10. In case of proxy voting,
please identify:
|
|
Name of the proxy holder
|
|
|
The number and % of voting rights
held
|
|
|
The date until which the voting
rights will be held
|
|
|
|
|
11.
Additional information xvi
|
|
Faron Share Offering
20.6.2024
|
|
|
|
|
| |
|
Place of completion
|
Lausanne, Switzerland
|
|
Date
of completion
|
20.6.2024
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
HOLFZGZVMDZGDZM
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Oct 2024 to Nov 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Nov 2023 to Nov 2024
